回复：纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果 - Suppr | 超能文献

Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.

作者信息

Grabbert Markus, Grosu Anca L, Zamboglou Constantinos, Gratzke Christian

机构信息

Department of Urology, University Hospital Freiburg, Freiburg, Germany.

Department of Radiotherapy, University Hospital Freiburg, Freiburg, Germany.

出版信息

Eur Urol. 2022 Jun;81(6):622. doi: 10.1016/j.eururo.2022.02.017. Epub 2022 Mar 10.

DOI:10.1016/j.eururo.2022.02.017

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.回复：纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果

Eur Urol. 2022 Jun;81(6):622. doi: 10.1016/j.eururo.2022.02.017. Epub 2022 Mar 10.

2

Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.回复：克里斯蒂娜·马西尼、钦齐亚·约蒂、乌戈·德·乔治等。纳武单抗联合立体定向体部放疗用于转移性肾细胞癌经治患者。II期NIVES研究结果。《欧洲泌尿外科杂志》。2022年；81卷：274 - 82页。

Eur Urol. 2022 Apr;81(4):e98-e99. doi: 10.1016/j.eururo.2021.11.034. Epub 2022 Jan 4.

3

Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.回复：克里斯蒂娜·马西尼、钦齐亚·约蒂、乌戈·德·乔治等。纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果。《欧洲泌尿外科杂志》。2022年；81卷：274 - 82页。

Eur Urol. 2022 Apr;81(4):e96-e97. doi: 10.1016/j.eururo.2021.11.035. Epub 2022 Jan 3.

4

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.纳武利尤单抗联合立体定向放疗治疗预处理转移性肾细胞癌患者：Ⅱ期 NIVES 研究结果。

Eur Urol. 2022 Mar;81(3):274-282. doi: 10.1016/j.eururo.2021.09.016. Epub 2021 Oct 1.

5

Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.回复：纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果

Eur Urol. 2022 Feb;81(2):216. doi: 10.1016/j.eururo.2021.11.003. Epub 2021 Nov 20.

6

Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.脊柱立体定向放射外科联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。

J Neurosurg Spine. 2016 Dec;25(6):766-774. doi: 10.3171/2016.4.SPINE16229. Epub 2016 Jul 8.

7

Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.消融治疗与单纯姑息性放疗联合纳武利尤单抗治疗转移性肾和肺癌患者的获益。

Clin Transl Oncol. 2019 Jul;21(7):933-938. doi: 10.1007/s12094-018-02005-7. Epub 2018 Dec 18.

8

Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.晚期肾细胞癌患者的放射治疗。

Urol Clin North Am. 2020 Aug;47(3):399-411. doi: 10.1016/j.ucl.2020.04.011. Epub 2020 Jun 8.

9

Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature.肾细胞癌放疗联合抗PD-1治疗后出现超进展性疾病：一例病例报告及文献复习

BMC Urol. 2021 Mar 21;21(1):42. doi: 10.1186/s12894-021-00813-8.

10

Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates.关于：卡博替尼联合纳武单抗治疗非透明细胞肾细胞癌患者的II期试验及基因组相关性

Eur Urol. 2022 Sep;82(3):331-332. doi: 10.1016/j.eururo.2022.04.033. Epub 2022 May 20.

引用本文的文献

1

Impact of different nephrectomy types on M0 renal cell carcinoma outcomes in a propensity score matching and deep learning study.基于倾向评分匹配和深度学习研究的不同肾切除术式对 M0 期肾细胞癌结局的影响。

Sci Rep. 2024 Nov 11;14(1):27571. doi: 10.1038/s41598-024-79070-2.